Accelovance, a global contract research organization (CRO) focusing in oncology, vaccines, and general medicine has signed a merger agreement with Linical, a leading CRO based in Asia in the fields of oncology, immunology, and neurology. 

The new company will offer clients even deeper oncology expertise, with combined scientific strength in both the early and late phases of clinical development. In addition, the company will provide significant leadership in many other therapeutic areas – for example, Linical’s experience in neurology and immunology, as well as Accelovance’s offerings in vaccines, dermatology, pain, women’s health, and nutrition. Together, the companies’ services cover the entire drug life cycle, offering clients a one-stop provider for drug development, clinical research, a patient-focused call center, medical affairs, and post-marketing services.

Stephen J. Trevisan, chief executive officer of Accelovance noted, “This is an exciting milestone for Accelovance, allowing us to further expand our global bandwidth. Linical’s expertise in oncology and immunology aligns perfectly with our therapeutic focus, and their strong heritage in neurology further enhances our service offering for clients. We are pleased to be working together with an organization that shares our mission of delivering exceptional execution to our clients in clinical research.”

Mr. Kazuhiro Hatano, president & chief executive officer, Linical Co., Ltd., said, “This transaction will enable us to reinforce our capability and capacity in the USA as well as to strengthen our global network to respond to clients’ needs of conducting large-scale multinational clinical trials. We will continue to work towards our core values of delivering high quality and reliable services to our clients worldwide.”